MedDataX Logo

Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata

NCT ID: NCT02350023

Last Updated: 2015-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. The two agents have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. Topical prostaglandins like latanoprost have also been used for this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. However, the two agents i.e. topical corticosteroids and topical latanoprost have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alopecia Areata

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Topical latanoprost

Topical latanoprost 0.005%

Group Type ACTIVE_COMPARATOR

Topical latanoprost 0.005%

Intervention Type DRUG

Local application of the drug on affected skin/scalp

Topical betamethasone

Topical betamethasone 0.05%

Group Type ACTIVE_COMPARATOR

Topical betamethasone 0.05%

Intervention Type DRUG

Local application of the drug on affected skin/scalp

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Topical latanoprost 0.005%

Local application of the drug on affected skin/scalp

Intervention Type DRUG

Topical betamethasone 0.05%

Local application of the drug on affected skin/scalp

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Cases of AA involving scalp and beard area, having 5 or less patches in all, involving less than 40% area

* Stable disease without appearance of new patch or increase in size of existing patch for at least 15 days

Exclusion Criteria

* • Pregnant and lactating women

* Patients on topical treatment for alopecia in the past fifteen days or on systemic treatment for alopecia in the past one month
* Presence of any contraindication for topical corticosteroids (local skin infections, skin atrophy) or latanoprost (pregnancy, lactation and dermatitis)
* Any other coexisting hair disorder (viz., trichotillomania, androgenetic alopecia, telogen effluvium)
* Extensive disease i.e. \>5 patches of AA or area involving \>40% area / alopecia totalis/ alopecia universalis/ ophiasis
Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sonali Bhat

Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept of Dermatology, PGIMER

Chandigarh, , India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

References

Explore related publications, articles, or registry entries linked to this study.

Bhat S, Handa S, De D. A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata. Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):42-48. doi: 10.25259/IJDVL_787_19.

Reference Type DERIVED
PMID: 33580923 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9121/PG-2Trg/12/8073

Identifier Type: -

Identifier Source: org_study_id